Architecting Trust in Global Pharmaceutical Supply
Cross Corporation is an Indian pharmaceutical manufacturer and exporter engaged in the development, registration, and global supply of high-quality finished pharmaceutical formulations for regulated and emerging healthcare markets.
Meet Our Founder & Director
Scientific rigor, deep regulatory understanding, and an uncompromised commitment to quality governance.
Smit Jariwala
Smit Jariwala is the Founder and Director of Cross Corporation, an India-based pharmaceutical manufacturing and export company. He has been actively associated with the healthcare and pharmaceutical industry since 2017, and with pharmaceutical exports, imports, and global regulatory compliance since 2021.
He holds a Bachelor’s degree in Chemistry and a Master’s degree in Industrial Chemistry, providing a strong technical foundation in pharmaceutical formulation, raw materials, synthesis processes, and quality systems.
Professionally, he has worked with leading USFDA, EUGMP, and NABH accredited healthcare organizations such as Zydus Cadila, Lupin, and Metropolis Healthcare, holding management-level roles where he gained extensive exposure to manufacturing operations, quality assurance, regulatory compliance, and international coordination.
His hands-on experience includes CDSCO approvals, NDPS compliance, COPP issuance, export NOCs, and product registrations with Ministries of Health (MOH) in importing countries, enabling Cross Corporation to manage complex and highly regulated products with confidence.
Our Guiding Philosophy
At Cross Corporation, we believe that trust, compliance, and consistency are the foundation of international pharmaceutical trade. Every project is approached with a long-term vision — from initial registration batches to scalable commercial supply — ensuring reliability for both manufacturers and overseas partners.
Our business model is structured to meet the expectations of regulated and semi-regulated markets, allowing overseas partners to work directly with a technically competent Indian manufacturer and reliable supplier on regular basis.
R&D & Formulation Capabilities
Cross Corporation specializes in product-specific development and R&D-driven manufacturing, tailoring formulations to meet country-specific regulatory, climatic, and market requirements.
We actively monitor upcoming patent expiries and focus on developing timely generic versions to enable rapid market entry immediately after patent expiration. On demand, we utilize high-grade raw materials sourced from USFDA-approved manufacturing units.
Our Manufacturing Units in India
Strategically positioned across India's prominent pharmaceutical industrial hubs in Gujarat and Himachal Pradesh.
Changodar Facility
Address:
447, Nr. Bajaj Food, Changodar, Ahmedabad, Gujarat, India
Dedicated to high-speed solid dosage formulations, specialized packing lines, and QA release protocols.
Baddi Facility
Address:
Vill Bhud, NH21-A, Nalagarh Road, Baddi, Distt. Solan, Himachal Pradesh, India
High-capacity production facility equipped for complex generics, combination products, and climatic zone stability.
Padavala Facility
Address:
Survey No: 480, Plot No. 36, 37, 38 Rachna Industrial Zone, Padavala, Rajkot, Gujarat 360022
Modern formulation infrastructure with dedicated cleanrooms and raw material quarantine compliance.
Cross Corporation Corporate Office
9/153 B, Ground Floor, Pagathiya Street, Wadifaliya, Surat, Gujarat, India - 395001
Regulatory & Compliance Integrity
Navigating global compliance frameworks with transparency, documentation precision, and statutory adherence.
GMP Aligned Systems
Manufacturing operations strictly aligned with USFDA, EUGMP, GCC, and WHO-GMP expectations.
COPP & Dossier Suite
Full preparation of Certificate of Pharmaceutical Product (COPP), MOA, COA, and ACTD/CTD dossiers.
NDPS Act Governance
Complete legal and regulatory infrastructure for handling controlled substances and narcotic drugs.
MOH Collaborations
Coordinating with Indian regulatory bodies (CDSCO, FDCA) and overseas Ministries of Health for prompt approvals.